No Data
2024 Earnings Advance Loss Announcement
Thalys Medical Technology Group Corporation (603716.SH): A forecasted loss of 0.21 billion to 0.25 billion yuan in 2024.
On January 17, Gelonghui reported that Thalys Medical Technology Group Corporation (603716.SH) announced an expected annual performance loss for 2024, estimating that the net income attributable to shareholders of the listed company will be between -0.21 billion yuan and -0.25 billion yuan in 2024; it is expected that the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses will be between -0.145 billion yuan and -0.19 billion yuan in 2024.
China Resources Sanjiu Medical & Pharmaceutical (000999.SZ): Currently, the company has no equity cooperation with Thalys Medical Technology Group Corporation.
On December 11, Gelonghui reported that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) stated on the investor interaction platform that the company currently has no equity cooperation with Thalys Medical Technology Group Corporation.
Thalys Medical Technology Group (SHSE:603716) Adds CN¥381m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 45%
Improved Revenues Required Before Thalys Medical Technology Group Corporation (SHSE:603716) Stock's 32% Jump Looks Justified
Celi Healthcare: third quarter report 2024
